US3476855A - Sterilizing and enhancing activity of a finely divided cartilage powder - Google Patents
Sterilizing and enhancing activity of a finely divided cartilage powder Download PDFInfo
- Publication number
- US3476855A US3476855A US698426A US3476855DA US3476855A US 3476855 A US3476855 A US 3476855A US 698426 A US698426 A US 698426A US 3476855D A US3476855D A US 3476855DA US 3476855 A US3476855 A US 3476855A
- Authority
- US
- United States
- Prior art keywords
- cartilage
- powder
- wound
- healing
- wounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000000845 cartilage Anatomy 0.000 title description 143
- 239000000843 powder Substances 0.000 title description 74
- 230000001954 sterilising effect Effects 0.000 title description 11
- 230000002708 enhancing effect Effects 0.000 title description 6
- 239000000284 extract Substances 0.000 description 68
- 206010052428 Wound Diseases 0.000 description 66
- 208000027418 Wounds and injury Diseases 0.000 description 65
- 230000000694 effects Effects 0.000 description 32
- 238000012360 testing method Methods 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 28
- 230000035876 healing Effects 0.000 description 28
- 239000002245 particle Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 230000029663 wound healing Effects 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 241000283690 Bos taurus Species 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 238000000605 extraction Methods 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 229940111202 pepsin Drugs 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000002674 ointment Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000000227 grinding Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 208000025865 Ulcer Diseases 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 244000309466 calf Species 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 235000011089 carbon dioxide Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 5
- 229910052753 mercury Inorganic materials 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 208000002260 Keloid Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000001099 ammonium carbonate Substances 0.000 description 4
- 235000012501 ammonium carbonate Nutrition 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 210000001117 keloid Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000938605 Crocodylia Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010023330 Keloid scar Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000002847 Surgical Wound Diseases 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 238000000498 ball milling Methods 0.000 description 3
- -1 car ragbeenan Polymers 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000003621 hammer milling Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101100027969 Caenorhabditis elegans old-1 gene Proteins 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000004280 Sodium formate Substances 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 2
- 235000019254 sodium formate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010073358 Anal squamous cell carcinoma Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000270725 Caiman Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 208000009344 Penetrating Wounds Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 208000032107 Rigor Mortis Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000270506 Tupinambis Species 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000009799 cystectomy Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000012820 exploratory laparotomy Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000002443 herniorraphy Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000007455 ileostomy Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 description 1
- 229960003868 paraldehyde Drugs 0.000 description 1
- 206010033898 parapsoriasis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000001966 tensiometry Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000002383 tung oil Substances 0.000 description 1
- 230000002620 ureteric effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
Definitions
- the particle size of the cartilage used has a surprisingly profound effect on the rate of healing'gand on the strength of the healed tissues. Not only is the ,rate of healing increased as the particle size of the cartilage is decreased, but also the manner or the process by which the cartilage is pulverized and the conditions prevailing during the pulverizing have a profound bearing on the results obtained with the cartilage powder.
- the effectiveness of the present invention has been demonstrated in comparative tests to be highly superior to results obtained on animals treated with either collagen, car ragbeenan, chondroitin sulfate, chondromucoprotein, fibrinogen, gelatin, talc, bone flour or systemic d methionine.
- cartilage taken from the partly calcified skeletons (including foetal skeletons) of very young or newly born animals is much more effective in accelerating the healing of wounds than was the case with the bovine tracheal cartilage powder on which previous observations were based, which included substantial quantities of coarse adult cartilage powder.
- the young animal is not over six months old.
- the present invention relates preferably to young cartilage, i.e. from young animals or young or newly regenerated cartilage from older animals as reptiles, whether finely divided or not, and cartilage from mature animals in finely divided (average particle size 40 microns or less) particle form, it is to be understood that the invention encompasses such cartilage in either the form which would in maturity retain the cartilaginous form or which would in maturity ossify to bone.
- the cartilage may be prepared by any suitable means to result in a product which is essentially pure cartilage substance free from adhering tissue, which may have been removed by acid-pepsin or other suitable enzyme treatment, with or without mechanical assistance, or otherwise.
- extraction aids those which are either volatile and therefore can be readily removed from the extract by volatilization such as for example ammonia or ammonium carbonate, or such materials which it remaining in the extract would cause no harm is applied either topically or introduced parenterally.
- Dialysis may be employed to remove undesired salts or other dialyzable material which may be present.
- Other extraction aids are urea, sodium citrate, disodium phosphate, trisodium phosphate, sodium formate, sodium chloride, and similar compounds or mixtures of them.
- the present invention provide dosage units of effective wound-helaing quantity of cartilage powder from a young animal, or from a mature animal, having average particle size between about 1 micron and about 40 microns, or a substantial maximum particle size of about 70 microns, incorporated into a clinically acceptable wound-healing carrier vehicle such as unguent, oil, salve, solution, extract, powder, etc.
- a clinically acceptable wound-healing carrier vehicle such as unguent, oil, salve, solution, extract, powder, etc.
- the invention also contemplates methods of enhancing the wound-healing activity of a cartilage powder and of restoring wound-healing activity in substantially inactivated cartilage powder including partially deactivated cartilage powder. Novel methods are also provided whereby finely divided cartilage powder may be stabilized before, during or after the final comminution stage of production thereof.
- Various techniques for the extraction of active wound-healing components, agents, and compositions from cartilage powder are included within the present invention.
- the cartilage powder as well as the extract were effective when they were absorbed or incorporated with surgical gauze which then was applied to the wound and when the same materials were applied by spraying onto the wound.
- clinically acceptable carrier vehicles for the effective cartilage powder or extract such as salves based on aqueous gels such as those from alginates, gum tragacanth, gelatin, gluten, casein, polyvinylpyrrolidone, textran and many others are effective in many applications. They are also convenient to apply especially over large areas such as is the case with burns.
- the effective cartilage powder or cartilage extracts suspended in oils such as tung oil, corn oil, olive oil, or linseed oil, may be applied directly to wounds.
- oils such as tung oil, corn oil, olive oil, or linseed oil
- the oil dispersions may be emulsified in water, forming oil-in-water type emulsions, or conversely, water may be emulsified in the oil dispersions forming water-in-oil type emulsions.
- the cartilage and cartilage extracts dispersed in aqueous or oil carriers may be applied directly to the wounds by spraying, brushing, by impregnating in bandaging materials or by any other means which makes it possible to bring the cartilage or its extract into intimate contact with the tissues.
- cartilage or cartilage extract preparations may be introduced subcutaneously, intra-muscularly, intravenously, or through suppositories introduced into rectal or other cavities.
- Cartilage powders dispersed in suitable oils have been successfully administered orally.
- Cartilage powder may be administered, as orally, in the form of pellets such as tablets or capsules.
- the cartilage powder by incorporating the cartilage powder onto silica gel or other gel forming materials which are capable of coating the stomach walls, the rate of healing of stomach ulcers may be noticeably increased.
- the invention has been used with humans in treatment of keloids (hardened scar tissue).
- the keloid was initially cut out, and resutured in the presence of the calf cartilage powder of the invention. After more than six months periodic observation, the keloid did not reappear and apparently the invention prevented the re-formation of the keloid scar tissue, contrary to the usual experience of frequent recurrence of keloid formation.
- the cartilage saline extract of this invention has also demonstrated a marked anti-inflammatory effect. For example, as when introduced parenterally in the areas affected by psoriasis, almost immediate reduction of the inflammation was observed.
- the statistical average of scores of tests involving the application of the cartilage of the present invention shows that there were produced increases of over 50% in the tensile strengths of seven-day old midline abdominal wounds in rats.
- the increase in wound-healing rate was even further enhanced when a combination of optimal size (between about 10 and about 30 microns average diameter) and optimal age of the cartilage source (calf) were combined, in an average of which cases maximal increase in wound tensile strength substantially higher than 50% was achieved.
- Wound strength increase averaging 5 0% results in less likelihood of wound disaster, less likelihood of wound infection, the capability of removing sutures earlier with attendant further lessening the likelihood of infection as well as further acceleration in final wound-healing rate, thereby resulting in earlier discharge of the patient from care and safer post-care experience.
- the cartilage treated wound ages in accordance with the present invention, it does not become a mass of essentially acellular collagen as does the cicatrix of the untreated wound. Instead, it continues to proliferate in humans actively up to 40 days after wound and frequently longer. It does not however, become hypertrophic or keloidal, and, in fact, appears less bulky than the corresponding control wounds.
- the local use of the finely ground calf cartilage powder is of great clinical value in the treatment of non-granulating wounds of 50 different kinds, without untoward effects, either locally or systemically, as demonstrated in application to the primarily closed wounds of 87 human surgical incisions in a wide variety of procedures. There was no immediate or late evidence of antigenicity.
- the cartilage preparations of the present invention have been successfully utilized to accelerate and to improve the healing of the following types of wounds, either by topical application or by injection of saline extract: chemical burns, third degree skin burns, radioactive injury, chest wall, abdominal and other wounds, operative and post-operative wounds, penetrating wounds such as those of thorax and abdomen, ulcers due to arteriosclerosis and to trophic disturbance, ulcers of skin, gangrene of skin due to trauma or physical agent or to undetermined cause, dermatitis, lupus erythematosus with ulcer, keloids, atopic eczema, parapsoriasis and psoriasis.
- Other types of wounds also have responded successfully to the cartilage preparations of this invention with improved results.
- the invention is especially useful in cases involving cortisone or other steroid treatment (known to retard healing) or involving diabetes.
- the wound tensile strength at seven days is determined in millimeters of mercury by a modification of the technique of the method illustrated in the publication cited above.
- the rat to be tested is killed by an intracardiac injection of paraldehyde or by exposure to toxic fumes such as to diethyl ether.
- the test is made prior to the onset of rigor mortis.
- a rubber latex prophylactic pouch is inserted into the peritoneal cavity through a defect made with a Kelly clamp in the apex of the vagina.
- the rotary air pump connected to the pouch is turned on regulating it in such a manner that the air pressure will increase at a rate of millimeters of mercury every five seconds.
- the pressure at which the wound splits and the pouch extrudes itself (wholly or in part) through the defect is recorded as the tensile strength of the wound. This is also a quantitive measure of the degree of healing or rate of healing achieved in the experiments.
- Example 1 Cartilage pebble mill-ground
- the tracheas of healthy adult beef cattle were removed within 30 to 60 minutes after the animals were slaughtered.
- the tracheas were then either processed immediately with an acid-pepsin solution or they were frozen to preserve them, in which case the acid-pepsin digestion may be deferred.
- the tracheas either fresh or previously frozen were then digested for about six hours at 50 C. in an loaded with one-inch size (average) flint pebbles in a weight ratio of 1 cartilage to 2 pebbles. Dry Ice (CO was then put on top of the mill charge and the mill was kept open for five minutes to allow the CO to displace the air in the mill.
- CO Dry Ice
- the lid of the mill was then clamped on tight and the mill rotated as is customary in the performance of the grinding operation, The grinding was carried out at about 20 C. for 96 hours.
- the ground cartilage was screened through a 325 mesh nylon screen, thereby confining the active cartilage powder to particles less than about 40 microns in side, and having average or majority particle size between about 5 and 10 microns.
- the cartilage was acid-pepsin digested as in Example 1, granulated, and then without drying was suspended in the extracting liquid and then transferred into a pebble mill which was charged to of its volume with flint pebbles of average size, one inch diameter.
- the ratio of the cartilage to extracting liquid was kept to 25:75.
- the liquid suspension was charged into the mill in a quantity just sufficient to fill the voids of the pebbles with the top of the pebbles barely covered by the liquid.
- the air was then purged from the mill with nitrogen and the mill closed.
- the mill was allowed to run for six hours at between 3 C. and 4 C. which resulted in a medium fine grinding of the cartilage and in the simultaneous extraction of the active wound-healing agent from the cartilage.
- the mill was emptied, the fluid paste strained free of the pebbles, the fluid transferred into a centrifuge operated at 6000 r.p.rn. and at a temperature of between 3 C. and 4 C. After one-half hour the centrifuge was stopped and the supernatant liquid strained through a 400 mesh nylon screen. If the strained extract was cloudy, it was returned to the centrifuge and the centrifuging repeated until a clear slightly opalescent extract was obtained.
- the extracts were stored at 4 C, preserved with 1: 10,- 000 sodium ethyl mercuri thiosalicylate.
- Norm-The isotonic saline solution was prepared with distilled water and contained 0.9% NaOl.
- acetic acid U.S.l glacial
- pepsin NF. IX grade, 3500 activity
- the cartilage was dried in vacuum 20 mm. mercury at 80 C. The dried cartilage was defatted by extracting it with a solvent, such as hexane. It was then granulated.
- the granulated purified cartilage was ground to a fine
- satisfactory powders may be obtained by ball milling, hammer milling in inert atmosphere. While ball or pebble milling the cartilage with the extracting liquid gives satisfactory results, other methods, such as mixing the cartilage powders in the liquids with a high speed, high shear, closed turbine mixer or passing the extraction mixture through a pressure homogenizer, preferably at pressures in excess of 4000 p.s.i., will also give extracts of high powder in a laboratory four-quart size porcelain jar mill, activity.
- Example lApray-drying cartilage extracts Dry concentrates were prepared from cartilage extracts as follows:
- a laboratory Bowen type spray-dryer was used with the following modifications. In place of the oil furnace, electric heating coils were used to supply the heat energy necessary for the evaporation of the volatile portions of the extracts. Instead of air, nitrogen was used for the hot gas. A vaned disc, rotating at about 20,000 r.p.m. was used to atomize the extracts. The inlet gas temperature was held to about 280 F., the outlet temperature was between 140 F. and 160 F. The dryer was used as a closed system dryer with the exclusion of oxygen to avoid degrading the active material during the evaporation of the water.
- the solids percen means percent of solids in the extracting liquid as determined by drying at 100 C. for two hours.
- Yield percent means the dry solids percent obtained from the liquid by the drying process.
- the spray-dried powders were stored in tightly closed glass jars in a refrigerator at 4 C.
- Example 4 Cartilage extracts applied to wound by swabbing to 5.75 cm. longitudinal midline abdominal incision of the female rat.
- Thyreotrophic hormone 0.008 U.S.P. unit/mgm.
- Example 7 This example demonstrates the value of reconstituted spray-dried and freeze-dried extracts in the healing of wounds.
- the dried extracts were dissolved either in water or in isotonic saline solution, depending on the salt content of the original preparation. The solutions were adjusted to correspond with the solids content of the extracts from which the dried materials were prepared. The solutions were applied by parenteral injections into rats as in Example 5.
- Example 8 This example demonstrates the value of intravenous injections of cartilage extracts or solutions of dried extracts in the healing of wounds. These were made on dogs with circular incisions. Wounds were not sutured but protected only with sterile dressing. The rate of healing was measured by observing the degree of granulation as compared with the control.
- Rate of Extract wound healing (percent) 1. None-Isotonic saline-control 100 Example No.
- Example '9 This example demonstrates the effect of applying liquid cartilage extracts on open wounds.
- Porous fabric i.e. surgical gauze was saturated with the extracts and applied to the open and unsutured wounds while still wet. Tests were made on dogs. The rate of healing was measured by the observed degree of granulation.
- Example 10 This example demonstrates the effect of applying dried cartilage extract on open wounds.
- Porous fabric i.e. surgical gauze, was saturated with the extracts, dried to a moisture content of about at 30 C. and at a pressure of 50 mm. mercury. The dried gauze was applied to the open and unsutured wounds. Tests and observations were as in Example 9.
- Rate of Cartilage extract wound healing (percent) 1. Noneisotonic saline-control Example No.
- Example 11 These tests involved the intravenous injection of cartilage extracts combined with one or more blood extenders, such as whole blood, blood plasma, and a plasma substitute, namely polyvinylpyrrolidone or dextran. Tests were made on dogs. In carrying out these tests 100 cc. blood was taken from the animal and treated as follows:
- the blood was mixed with 10 cc. cartilage extract and reinjected into the same animal.
- the plasma was obtained from the blood mixed with 10 cc. cartilage extract and reinjected into the same animal from which the blood was obtained.
- control animals were treated as follows:
- Control -2 The blood taken as in case of Control 1, the plasma separated and reinjected into the same animal;
- Control 3 The blood was taken from the animal as above in case of Control 1, and replaced with a saline solution of 3.5% polyvinylpyrrolidone viscosity type K-30.
- Example 2- III 120 Example 21- 150 xample 21 145 Example 2]
- Example 2p 150 Example 2p II
- Example 2-p III 136 The animals used in these experiments weighed not less than 30 lbs. each.
- Example 12.-Sterilization with an antiseptic alcohol 70% Mix the calf cartilage powder of the invention with an excess of about 70% (volume) ethyl alcohol. A sufiicient excess of alcohol is present when the cartilage powder forms a mobile slurry with the powder. The particle size of the powder controls the volume of alcohol required to form the mobile slurry. The smaller the particle size the larger the volume of alcohol is required.
- the alcohol slurry of the cartilage powder is best mixed at a rate to keep the powder suspended in the liquid.
- the cartilage swells somewhat and becomes gummy under the influence of the 70% alcohol.
- the cartilage sediment mixed with the anhydrous alcohol, is dehydrated regaining substantially its original particle size and losing its gumminess. This dehydrated cartilage can be readily filtered and dries to a free flowing powder.
- Example 13 Sterilization with isopropyl alcohol Anhydrous isopropyl alcohol sterilizes the cartilage as well as 70% ethyl alcohol and in about the same time, i.e., about 30 minutes, without swelling the cartilage particles or causing gumminess.
- the cartilage slurry prepared with isopropyl alcohol can be readily filtered and the filter cake so obtained can be dried to a free flowing powder.
- the sterilization either with ethyl alcohol or with isopropyl alcohol can be carried out satisfactorily at ambient room temperatures, although sterilization at elevated temperatures may reduce the time required.
- Example 14 Stemilization of the cartilage powder by heat Cartilage powder of the invention, surprisingly, is
- sterilized without loss of wound healing activity, by heating it to about 125-132 C. for 3-4 hours, substantially in the absence of air or oxygen.
- Other temperatures as low as 110 C., may be utilized, but for longer periods of time to achieve sterilization.
- the preferred procedure is to place the cartilage powder in a vessel with some Dry Ice over it and then covering the vessel loosely with a metal foil.
- the vessel is placed in a vacuum oven, then oven is connected with a vacuum pump and the air is evacuated to a vacuum of about 10 mm. of mercury.
- the oven is then heated to about 127 C. and held there for about four hours.
- the heat sterilized powder is ready for clinical use.
- Example 15 Reactivation and enhancement of cartilage by heat in the absence of oxygen This example illustrates lowering of the activity of calf cartilage powder when milled in the presence of air, and air together with heat, respectively, followed by the restoration and further enhancement of the wound-healing activity when the partially or totally inactivated material is exposed to heat of about 127 C. for between 5 hours to 50 hours and in the virtual absence of air or oxygen (Tests 6 and 8).
- the cartilage powder was inactivated by hammer milling it under conditions of excessive aeration and some generation of heat (Test 5).
- the activity of the cartilage was lowered to about one-third of its activity by ball milling it in the presence of air (Test 7), as compared with the same material ball milled in a C atmosphere (Test 4).
- the heating of the cartilage was done in the following manner: A vacuum oven (Freas, Size No. 504, Fisher Scientific Co.) was loaded with the cartilage powder and with a small quantity of Dry Ice (solid CO About 15 to 25 grams of the Dry Ice were placed in an open dish in the oven. The door of the oven was closed, the air evacuated to about 10 mm. pressure, the vacuum pump was disconnected, and the heating cycle started. During heating there was some pressure build-up in the oven caused by the expansion of the Dry Ice as it becomes gaseous carbon dioxide.
- Rate of wound (7) Calf cartilage, Lot 2AX, ball milled in air (8) #7, heated in CO for /2 hrs., 127
- test results were based on 20 to over 40 pairs of animals (Sherman strain albino rats) for each of the eight tests enumerated above and the percent figure represents the statistical average of all such tests.
- Comparison of Test 3 with Test 2 shows that heat sterilization of the powder of this invention may be accomplished together with enhancement (130.5 vs. 127.7%) of wound healing rate.
- Comparison of Test 5 with Test 4 shows that highly effective powder of this invention may be completely deactivated by hammer-milling air with heat generation.
- Comparison of Test 8 with Test 7 shows that heating of the degraded powder of Test 7 in CO at elevated temperature reactivates the material to a highly effective rate of wound healing.
- Example 16 Forty wounds involving a wide spectrum of human chronic non-healing types of ulcers were treated according to the present invention.
- the wound was thoroughly cleansed with hydrogen peroxide, and washed with alcohol. It was dried with gauze.
- the cartilage preparation was applied by atomizing the powder onto the surface and into the wound. In 38 of the 40 cases this treatment resulted in the transformation of the wound surface from a non-granulating, sluggish, dirty grey surface to a typical pink, healthy granulating bed within ten days. In the other two cases a somewhat longer time was required.
- Example 17 The cartilage powder of the invention was atomized into 83 surgical wounds in 39 human patients with 47 operations, as follows:
- Example 18 Calf tracheal cartilage powder having maximum particle size of 40 microns was mixed with about an equal part of anhydrous propylene glycol. This premix was 13 then added to Neobase (an ointment base made by Burroughs -Wellcome & Co. of Tuckahoe, N.Y.) which contains the following ingredients:
- Example 19 An ointment particularly useful with surgical gauze was formulated by mixing the following:
- This ointment is useful in certain dermatological applications and the physical properties may be further adjusted and controlled by varying the ratios of the polyethylene glycols or adding required amounts of propylene glycol and/or glycerol.
- cartilage with substantially greater potency is obtained from the skeletons of very young animals.
- the highest potency material is generally obtained from animals less than one month old, although cartilage from adolescent animals taken before maturity may be used in this invention without excessively fine grinding. Young animals are intended to mean those which are still adolescent and have not yet reached maturity. Cartilage from foetal skeletons is often effective.
- Finely divided cartilage from other mammals, in addition to bovine and porcine and canine, is effective in healing wounds in accordance with the present invention: for example, finely divided cartilage powder from rat trachea and the human knee have been successfully utilized in accordance with the invention; so also with other animals such as the finely divided cartilage of birds, fish, jaw-bone of shark, rib cage of a crocodile (South American caiman known to be one year old, as obtained from the New York City Zoological Gardens, in early adolescence). Finely divided reptile cartilage is particularly elfective in view of the extraordinary ability of the reptiles to regenerate their tissues and even their limbs.
- the cartilage powder may be dusted on the wound or atomized on it. It may also be applied in the form of ointment on the wound, as exemplified above.
- the extract may also be applied directly to the wound by spraying it on the wound, swabbing it on, or brushing it on. Both the powder and the extract may be applied first to an absorbent medium which is then applied to the wound and held on by a bandage or adhesive tape, or other suitable means.
- the cartilage or the extract may be incorporated into tablets, capsules or suppositories and applied orally, rectally or in the vaginal or uteral passages. Implantation as pellets and injection of solution of the extract of the invention has been effective.
- Cartilage extracts may be injected subcutaneously, intramuscularly or intravenously.
- the dried extracts may be used as powders or they may be reconstituted and used as the original extracts.
- the wounds to which the active materials are applied may be sutured or may be left open without materially affecting the rate of healing.
- the active materials may be administered once, preferably within the first 24 hours of the incision; or they may be applied before the incision or they may be applied in several applications in succession. Irradiating the cartilage powder with ultraviolet radiation in the absence of oxygen increases its activity.
- the improvement which consists of the steps of (1) mixing, at a rate to keep the powder suspended in the liquid, such dried ground extracted cartilage powder, with a sufiicient excess of ethyl alcohol to form a mobile slurry, in which the cartilage swells and becomes somewhat gummy and is difficult to filter and forms a hard crust when dried, which has then to be ground to the original particle size; (2) centrifuging the slurry to form a firm cartilage sediment; (3) decanting the supernatant liquid and replacing References Cited UNITED STATES PA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
United States Patent M 3,476,855 STERILIZING AND ENHANCING ACTIVITY OF A FINELY DIVIDED CARTILAGE POWDER Leslie L. Balassa, Blooming Grove, N.Y. 10914 No Drawing. Original application Feb. 26, 1965, Ser. No. 435,693, now Patent No. 3,400,199, dated Sept. 3, 1968. Divided and this application Jan. 17, 1968, Ser. No. 698,426
Int. Cl. A61k 1 7/ 00, 27/00 U.S. Cl. 424-95 3 Claims ABSTRACT OF THE DISCLOSURE This application is a division of my copending application Ser. No. 435,693 filed Feb. 26, 1965, now U.S. Patent No. 3,400,199 issued Sept. 3, 1968.
It was observed some time ago that the healing of wounds of human patients is inhibited or retarded if the patients were at the same time undergoing cortisone treatment. It was found further that this inhibition of the healing of the wounds could be overcome in some instances by the use of cartilage powder applied locally.
It has also been shown that the healing of wounds has sometimes been accelerated by the use of rather coarse, hand-ground powder of acid-pepsin digested adult bovine tracheal cartilage having maximum particle size of about 400-450 microns. Experiments were carried out on albino Sherman strain female rats. There was observed a maximum average increase in the rate of healing and in the strength of the healed tissues of about 20% over that of the control animals, the control animals being those with wounds untreated.
One of the problems involved in healing wounds has long been recognized as occurring in a primarily closed incision. When a composition is applied to such a wound, any excess in amount of such application at least initially produces a negative effect, which has sometimes been called the interposition effect. This is the reduction in tensile strength observed when any substance is placed into a primarily closed Wound, even in very small amounts. In the test data reported in this specification where the negative results are reported for prior art compositions such as gelatin, talc, collagen, etc., as well as when the compositions of this invention had been deactivated or degraded by one process or another, it appears that a major contributing factor to the negative results has been the interposition effect. Thus, when the active composition of the invention demonstrates any improvement in the rate of wound-healing, it should be remembered that the improvement has occurred in spite of the initial handicap of the interposition effect which must be overcome. Similarly, care must be exercised to avoid the use of excess quantities of the material of the present invention, to reduce the initial interposition effect in topical applications.
Investigation has been made of many compositions in the past, among them chondroitin sulfate, chondromucoprotein, carregheenan and collagen, and in every instance 3,476,855 Patented Nov. 4, 1969 these have yielded no wound-healing effect whatever. Most have given small negative results, probably as a result of the interposition effect. Other compounds tested including local hyaluronic acid, glucuronic acid, n-acetylglucosamine, and lysozyme were tested for wound-healing activity without significanteffect. For example, parenteral injections on rats of the last three named substances were given on the first post-operative day. This time was chosen since it is on this day that injections of a saline extract of the cartilage of this invention have been shown to be effective. The local applications were at the same density as has been employed for such cartilage preparations (2 4 mg./cm. of wound surface), while the parenteral injections were made from 5% solutions and were 2 cc. and 5 cc. in volume. All these tests were without any significant positive result.
I have now found that the particle size of the cartilage used has a surprisingly profound effect on the rate of healing'gand on the strength of the healed tissues. Not only is the ,rate of healing increased as the particle size of the cartilage is decreased, but also the manner or the process by which the cartilage is pulverized and the conditions prevailing during the pulverizing have a profound bearing on the results obtained with the cartilage powder. The effectiveness of the present invention has been demonstrated in comparative tests to be highly superior to results obtained on animals treated with either collagen, car ragbeenan, chondroitin sulfate, chondromucoprotein, fibrinogen, gelatin, talc, bone flour or systemic d methionine. I have also found methods of further increasing the wound-healing activity of the effective powders of this invention and methods of reactivating such powders after they have been inadvertently deactivated or otherwise reduced in activity.
Furthermore, I found most unexpectedly that cartilage taken from the partly calcified skeletons (including foetal skeletons) of very young or newly born animals is much more effective in accelerating the healing of wounds than was the case with the bovine tracheal cartilage powder on which previous observations were based, which included substantial quantities of coarse adult cartilage powder. Preferably the young animal is not over six months old.
While the present invention relates preferably to young cartilage, i.e. from young animals or young or newly regenerated cartilage from older animals as reptiles, whether finely divided or not, and cartilage from mature animals in finely divided (average particle size 40 microns or less) particle form, it is to be understood that the invention encompasses such cartilage in either the form which would in maturity retain the cartilaginous form or which would in maturity ossify to bone.
The cartilage may be prepared by any suitable means to result in a product which is essentially pure cartilage substance free from adhering tissue, which may have been removed by acid-pepsin or other suitable enzyme treatment, with or without mechanical assistance, or otherwise.
I have succeeded in preparing highly effective extracts by the use of aqueous solutions of materials which are in the pH range of about 6.5 to 10, and preferably between 5 and 8, at the concentrations employed in preparing the extracts. I prefer to use as extraction aids those which are either volatile and therefore can be readily removed from the extract by volatilization such as for example ammonia or ammonium carbonate, or such materials which it remaining in the extract would cause no harm is applied either topically or introduced parenterally. Dialysis may be employed to remove undesired salts or other dialyzable material which may be present. Other extraction aids are urea, sodium citrate, disodium phosphate, trisodium phosphate, sodium formate, sodium chloride, and similar compounds or mixtures of them.
I succeeded in concentrating the extracts and even obtained dry extracts of substantially unimpaired activity and which could be redissolved or diluted back to the original strength with saline solution by concentrating the extracts in vacuum at low temperature or by freeze-drying them. subjecting the cartilage or the cartilage powder or the extracts of the invention to irradiation by ultraviolet light for a short period of time may increase the activity of the material to a noticeable degree. Irradiation with ionizing radiation such as gamma rays may also increase the activity of the cartilage.
I have found a surprising synergistic effect in the combination of cartilage powder or cartilage extract of the invention with growth hormone. This effect can be ob served both in topical and in parenteral applications.
I succeeded in obtaining satisfactory effects through oral administration of suitably pelletized or encapsulated cartilage powder or cartilage extracts of the invention.
The present invention provide dosage units of effective wound-helaing quantity of cartilage powder from a young animal, or from a mature animal, having average particle size between about 1 micron and about 40 microns, or a substantial maximum particle size of about 70 microns, incorporated into a clinically acceptable wound-healing carrier vehicle such as unguent, oil, salve, solution, extract, powder, etc. The invention also contemplates methods of enhancing the wound-healing activity of a cartilage powder and of restoring wound-healing activity in substantially inactivated cartilage powder including partially deactivated cartilage powder. Novel methods are also provided whereby finely divided cartilage powder may be stabilized before, during or after the final comminution stage of production thereof. Various techniques for the extraction of active wound-healing components, agents, and compositions from cartilage powder are included within the present invention.
I found that there were very great differences in the activity of the preparations, depending on the method used in their preparation, the auxiliaries or carrier employed, and in the technique of application. For example, the cartilage powder as well as the extract were effective when they were absorbed or incorporated with surgical gauze which then was applied to the wound and when the same materials were applied by spraying onto the wound. Also, clinically acceptable carrier vehicles for the effective cartilage powder or extract, such as salves based on aqueous gels such as those from alginates, gum tragacanth, gelatin, gluten, casein, polyvinylpyrrolidone, textran and many others are effective in many applications. They are also convenient to apply especially over large areas such as is the case with burns.
The effective cartilage powder or cartilage extracts suspended in oils such as tung oil, corn oil, olive oil, or linseed oil, may be applied directly to wounds. The oil dispersions may be emulsified in water, forming oil-in-water type emulsions, or conversely, water may be emulsified in the oil dispersions forming water-in-oil type emulsions. The cartilage and cartilage extracts dispersed in aqueous or oil carriers may be applied directly to the wounds by spraying, brushing, by impregnating in bandaging materials or by any other means which makes it possible to bring the cartilage or its extract into intimate contact with the tissues. In the case of parenteral applications the cartilage or cartilage extract preparations may be introduced subcutaneously, intra-muscularly, intravenously, or through suppositories introduced into rectal or other cavities. Cartilage powders dispersed in suitable oils have been successfully administered orally. Cartilage powder may be administered, as orally, in the form of pellets such as tablets or capsules. n the other hand, by incorporating the cartilage powder onto silica gel or other gel forming materials which are capable of coating the stomach walls, the rate of healing of stomach ulcers may be noticeably increased.
The invention has been used with humans in treatment of keloids (hardened scar tissue). The keloid was initially cut out, and resutured in the presence of the calf cartilage powder of the invention. After more than six months periodic observation, the keloid did not reappear and apparently the invention prevented the re-formation of the keloid scar tissue, contrary to the usual experience of frequent recurrence of keloid formation.
The cartilage saline extract of this invention has also demonstrated a marked anti-inflammatory effect. For example, as when introduced parenterally in the areas affected by psoriasis, almost immediate reduction of the inflammation was observed.
The statistical average of scores of tests involving the application of the cartilage of the present invention shows that there were produced increases of over 50% in the tensile strengths of seven-day old midline abdominal wounds in rats. The increase in wound-healing rate was even further enhanced when a combination of optimal size (between about 10 and about 30 microns average diameter) and optimal age of the cartilage source (calf) were combined, in an average of which cases maximal increase in wound tensile strength substantially higher than 50% was achieved. Wound strength increase averaging 5 0% results in less likelihood of wound disaster, less likelihood of wound infection, the capability of removing sutures earlier with attendant further lessening the likelihood of infection as well as further acceleration in final wound-healing rate, thereby resulting in earlier discharge of the patient from care and safer post-care experience.
Furthermore, as the cartilage treated wound ages in accordance with the present invention, it does not become a mass of essentially acellular collagen as does the cicatrix of the untreated wound. Instead, it continues to proliferate in humans actively up to 40 days after wound and frequently longer. It does not however, become hypertrophic or keloidal, and, in fact, appears less bulky than the corresponding control wounds. These observations point to the presence of inhibitory activity in the cartilage of the invention, in addition to the acceleratory factor.
The local use of the finely ground calf cartilage powder is of great clinical value in the treatment of non-granulating wounds of 50 different kinds, without untoward effects, either locally or systemically, as demonstrated in application to the primarily closed wounds of 87 human surgical incisions in a wide variety of procedures. There was no immediate or late evidence of antigenicity.
Controlled tensiometric observations in 15 human volunteers utilizing in each instance paired incisions in the same individual with tensiometry from 7 to 14 days after wounding have shown that the wound treated therein locally with the cartilage preparation of the present invention has been so much stronger than the untreated wounds as to exhibit a measured mean positive differential of approximately 50% over the control value.
The cartilage preparations of the present invention have been successfully utilized to accelerate and to improve the healing of the following types of wounds, either by topical application or by injection of saline extract: chemical burns, third degree skin burns, radioactive injury, chest wall, abdominal and other wounds, operative and post-operative wounds, penetrating wounds such as those of thorax and abdomen, ulcers due to arteriosclerosis and to trophic disturbance, ulcers of skin, gangrene of skin due to trauma or physical agent or to undetermined cause, dermatitis, lupus erythematosus with ulcer, keloids, atopic eczema, parapsoriasis and psoriasis. Other types of wounds also have responded successfully to the cartilage preparations of this invention with improved results. For example, the invention is especially useful in cases involving cortisone or other steroid treatment (known to retard healing) or involving diabetes.
Test methods: Unless otherwise stated, the effectiveness of the preparations of the examples herein was established in animal tests as described by J. Prudden, G. Nishihara and L. Baker in The Acceleration of Wound Healing with Cartilage-I, Surgery, Gynecology & Obstetrics, 105: 283 (1957).
Sherman strain albino female rats were employed in the tests. The preparation consisted of 5.5 centimeter midline abdominal incision under controlled conditions and closed with interrupted through-and-through sutures of No. 000 silk.
The wound tensile strength at seven days is determined in millimeters of mercury by a modification of the technique of the method illustrated in the publication cited above.
The rat to be tested is killed by an intracardiac injection of paraldehyde or by exposure to toxic fumes such as to diethyl ether. The test is made prior to the onset of rigor mortis. After the sutures have been removed from the wound, a rubber latex prophylactic pouch is inserted into the peritoneal cavity through a defect made with a Kelly clamp in the apex of the vagina. After the rubber pouch is in place, and the introitus has been snugged firmly (with a hemostat) around the tube leading to theperitoneal cavity, the rotary air pump connected to the pouch is turned on regulating it in such a manner that the air pressure will increase at a rate of millimeters of mercury every five seconds. The pressure at which the wound splits and the pouch extrudes itself (wholly or in part) through the defect is recorded as the tensile strength of the wound. This is also a quantitive measure of the degree of healing or rate of healing achieved in the experiments.
The following examples illustrate certain present preferred embodiments of the invention, and it isunderstood that other methods and embodiments within the spirit of the invention may be made without departing from the scope of the appended claims. Parts and ratios are bv weight except as otherwise stated.
Example 1.-Cartilage pebble mill-ground The tracheas of healthy adult beef cattle were removed within 30 to 60 minutes after the animals were slaughtered. The tracheas were then either processed immediately with an acid-pepsin solution or they were frozen to preserve them, in which case the acid-pepsin digestion may be deferred. The tracheas either fresh or previously frozen were then digested for about six hours at 50 C. in an loaded with one-inch size (average) flint pebbles in a weight ratio of 1 cartilage to 2 pebbles. Dry Ice (CO was then put on top of the mill charge and the mill was kept open for five minutes to allow the CO to displace the air in the mill. The lid of the mill was then clamped on tight and the mill rotated as is customary in the performance of the grinding operation, The grinding was carried out at about 20 C. for 96 hours. The ground cartilage was screened through a 325 mesh nylon screen, thereby confining the active cartilage powder to particles less than about 40 microns in side, and having average or majority particle size between about 5 and 10 microns.
Example 2.Preparation of cartilage extracts in the pebble mill Extracts of cartilage having high wound-healing activity were produced as follows:
The cartilage was acid-pepsin digested as in Example 1, granulated, and then without drying was suspended in the extracting liquid and then transferred into a pebble mill which was charged to of its volume with flint pebbles of average size, one inch diameter. The ratio of the cartilage to extracting liquid was kept to 25:75. The liquid suspension was charged into the mill in a quantity just sufficient to fill the voids of the pebbles with the top of the pebbles barely covered by the liquid. The air was then purged from the mill with nitrogen and the mill closed. The mill was allowed to run for six hours at between 3 C. and 4 C. which resulted in a medium fine grinding of the cartilage and in the simultaneous extraction of the active wound-healing agent from the cartilage.
At the end of the six-hour cycle, the mill was emptied, the fluid paste strained free of the pebbles, the fluid transferred into a centrifuge operated at 6000 r.p.rn. and at a temperature of between 3 C. and 4 C. After one-half hour the centrifuge was stopped and the supernatant liquid strained through a 400 mesh nylon screen. If the strained extract was cloudy, it was returned to the centrifuge and the centrifuging repeated until a clear slightly opalescent extract was obtained.
The extracts were stored at 4 C, preserved with 1: 10,- 000 sodium ethyl mercuri thiosalicylate.
The following extracts were thus prepared:
Total Solids of Clear Extrapt lily ei t Cartilage Source Extracting Liquid pmfint (2.) Bovine tracheal Distilled water 1,3 (b) Bovine tracheal Isotonic saline sol 5, 2 (0) Bovine tracheal Ammonia (28%) 1% in water 6, 5 (d) Bovine tracheal. 2% Urea in water. 9, 6 (e) Bovine tracheal. 1% Ammonium carbonate in water. 6, 4 (i) Bovine tracheal. 1% Disodium phosphate in water 6, 3 (g) Bovine tracheal- 3% Ammonium carbonate in water 7, 2 (h) Bovine tracheal. 1% Trisodium phosphate in water. 7, 6 (i) Bovine tracheal 1% Sodium citrate in water 7, 0 (j) Bovine tracheal 3% Sodium citrate in water. 9, 2 (k) Bovine tracheal 1% Sodium formate in water. 8. 2 (l) Piglet 1 day old. Isotonie saline solution 6, 4 (m) Piglet 1 day old-- 1% Ammonia (28%) in water 7, 1 (n) P glet 1 day old-.- 3% Ammonium carbonate in water 8, 1 (o) Piglet 1 day old. 3% Sodium citrate in water 10.0 (p) Cali 1 day old Isotonic saline solution 6, 2 (q) Call 1 day old 1% Ammonia (28%) in water 7. 3 (r) Cali 1 day old Isotonic saline solution plus ammonia to pH 8... 8. 2
Norm-The isotonic saline solution was prepared with distilled water and contained 0.9% NaOl.
aqueous solution containing 0.6% acetic acid (U.S.l glacial) and 0.3% pepsin (NF. IX grade, 3500 activity). After digestion the tracheal cartilage was removed from the acid-pepsin solution, washed first with water of about C. and then with water of about 25 C. until the effluent wash water showed no trace of pepsin or acetic acid. The cartilage was dried in vacuum 20 mm. mercury at 80 C. The dried cartilage was defatted by extracting it with a solvent, such as hexane. It was then granulated.
The granulated purified cartilage was ground to a fine In addition to pebble mill and fluid energy mill grinding, satisfactory powders may be obtained by ball milling, hammer milling in inert atmosphere. While ball or pebble milling the cartilage with the extracting liquid gives satisfactory results, other methods, such as mixing the cartilage powders in the liquids with a high speed, high shear, closed turbine mixer or passing the extraction mixture through a pressure homogenizer, preferably at pressures in excess of 4000 p.s.i., will also give extracts of high powder in a laboratory four-quart size porcelain jar mill, activity.
Example lApray-drying cartilage extracts Dry concentrates were prepared from cartilage extracts as follows:
A laboratory Bowen type spray-dryer was used with the following modifications. In place of the oil furnace, electric heating coils were used to supply the heat energy necessary for the evaporation of the volatile portions of the extracts. Instead of air, nitrogen was used for the hot gas. A vaned disc, rotating at about 20,000 r.p.m. was used to atomize the extracts. The inlet gas temperature was held to about 280 F., the outlet temperature was between 140 F. and 160 F. The dryer was used as a closed system dryer with the exclusion of oxygen to avoid degrading the active material during the evaporation of the water.
The following dry extracts were thus produced.
Appearance Solids Yield of ried Extract Used percent percent Powder a Example 2b- 5. 2 4. 8 S1. yellow. (10 Example 2c 6.5 6.2 D0. Example 2h 7. 6 7. 3 Do (d) Example 2-j 9. 2 8. 9 Ofi white. (e). Example 2-1. 6. 4 6. 2 S1. yellow. (f) Example 2-m. 7. 1 6.8 Do. (g) Example 2o 10. 0 9. 8 Ofi white. (h). Example 2p 6. 2 6.0 $1. yellow. (i) Example 2q 7.3 7. 1 D0. (j) Example 2-1'. 8. 2 8.0 Do.
The solids percen means percent of solids in the extracting liquid as determined by drying at 100 C. for two hours.
Yield percent means the dry solids percent obtained from the liquid by the drying process.
The spray-dried powders were stored in tightly closed glass jars in a refrigerator at 4 C.
Example 4 Cartilage extracts applied to wound by swabbing to 5.75 cm. longitudinal midline abdominal incision of the female rat.
Rate of wound Cartilage extract (liquid): healing (percent) 1. None-isotonic sa1inecontr0l 100 Example No.- 2 2 a 100 3 2.1) 125 4. 2-c 125 5. 2-d 125 6 2-e 125 7 2-f 130 8 2-g 115 9. 2-h 130 10. Z-i 130 11. 2-j 130 12. 2-k 135 13. 2-1 140 14. 2-m 140 15. 2-n 130 16. 20 135 17. 2-p 140 18. 2-q 145 19. 2-r 150 Example The effect of parenterally injected cartilage extracts on the healing of wounds. In each case 5 cc. of the extract was injected into the subcutaneous tissue on the rats back within 24 hours after the abdominal incision.
injected cartilage extracts combined with a bovine growth hormone. In each case 5 cc. of the extract was mixed with 10 mgm. of a bovine growth hormone, distributed by the Endocrinology Study Section of the National Institutes of Health through the pituitary hormone distribution program. Approximately assay of the growth hormone:
Adenocorticotrophic hormone-0.06 U.S.P. milliunit/ mgm.;
Prol-actin-O.l International unit/mgm.;
Vasopressin0.01 U.S.P. unit/mgm.;
Thyreotrophic hormone-0.008 U.S.P. unit/mgm.;
Oxytocin0.008 U.S.P. unit/mgm.;
Test animals and wounds are as stated in Example 5.
Rate of wound Cartilage extract (liquid): healing (percent) 1. None-isotonic saline-control 2. None-isotonic saline with growth hormone control 108 Example No. (with growth hormone) 3. 2-a 110 4. 2-b 130 5. 2-f 135 6. 2-i 135 7. 2-1 145 8. 2-p 145 9. 2*! Example 7 This example demonstrates the value of reconstituted spray-dried and freeze-dried extracts in the healing of wounds. The dried extracts were dissolved either in water or in isotonic saline solution, depending on the salt content of the original preparation. The solutions were adjusted to correspond with the solids content of the extracts from which the dried materials were prepared. The solutions were applied by parenteral injections into rats as in Example 5.
Rate of Wound Healing Dried Extract Solvent Percent (1). None Isotonlc saline-control. 100 g; Example 3a Wate (4) Example 3-e (5) Example 3-h .d0 (6) Example 3-] -do 140 Example 8 This example demonstrates the value of intravenous injections of cartilage extracts or solutions of dried extracts in the healing of wounds. These were made on dogs with circular incisions. Wounds were not sutured but protected only with sterile dressing. The rate of healing was measured by observing the degree of granulation as compared with the control.
Rate of Extract: wound healing (percent) 1. None-Isotonic saline-control 100 Example No.
Example '9 This example demonstrates the effect of applying liquid cartilage extracts on open wounds. Porous fabric, i.e. surgical gauze was saturated with the extracts and applied to the open and unsutured wounds while still wet. Tests were made on dogs. The rate of healing was measured by the observed degree of granulation.
Example 10 This example demonstrates the effect of applying dried cartilage extract on open wounds. Porous fabric, i.e. surgical gauze, was saturated with the extracts, dried to a moisture content of about at 30 C. and at a pressure of 50 mm. mercury. The dried gauze was applied to the open and unsutured wounds. Tests and observations were as in Example 9.
Rate of Cartilage extract: wound healing (percent) 1. Noneisotonic saline-control Example No.
Example 11 These tests involved the intravenous injection of cartilage extracts combined with one or more blood extenders, such as whole blood, blood plasma, and a plasma substitute, namely polyvinylpyrrolidone or dextran. Tests were made on dogs. In carrying out these tests 100 cc. blood was taken from the animal and treated as follows:
I. The blood was mixed with 10 cc. cartilage extract and reinjected into the same animal.
II. The plasma was obtained from the blood mixed with 10 cc. cartilage extract and reinjected into the same animal from which the blood was obtained.
III. The blood was replaced by an equal volume of an isotonic aqueous saline solution of polyvinylpyrrolidone 3.5%, viscosity grade K-30 and 10 cc. of a cartilage extract.
The control animals were treated as follows:
Control 1.100 cc. blood taken and then reinjected into the same animal;
Control -2.-The blood taken as in case of Control 1, the plasma separated and reinjected into the same animal;
Control 3.-The blood was taken from the animal as above in case of Control 1, and replaced with a saline solution of 3.5% polyvinylpyrrolidone viscosity type K-30.
Note: All blood samples taken were citrated to prevent coagulation. The rate of heating was measured by the observed degree of granulation.
Rate of Healing,
Cartilage Extract Test as per Percent (1). None, Control 1 2 one, Control 2 90 None, Control 3 85 Example 2b.. 130
Example 2b..
Example 2- III 120 Example 21- 150 xample 21 145 Example 2] Example 2p 150 Example 2p II Example 2-p III 136 The animals used in these experiments weighed not less than 30 lbs. each.
Example 12.-Sterilization with an antiseptic alcohol 70% Mix the calf cartilage powder of the invention with an excess of about 70% (volume) ethyl alcohol. A sufiicient excess of alcohol is present when the cartilage powder forms a mobile slurry with the powder. The particle size of the powder controls the volume of alcohol required to form the mobile slurry. The smaller the particle size the larger the volume of alcohol is required.
In general, 2 ml. alcohol mixed with each gram of a 30-micron average particle size cartilage powder is well in excess of the minimum required to form the slurry.
The alcohol slurry of the cartilage powder is best mixed at a rate to keep the powder suspended in the liquid. The cartilage swells somewhat and becomes gummy under the influence of the 70% alcohol.
In about 30 minutes the cartilage is sterilized by the alcohol. However, this sterilized cartilage, due to its swollen condition and gummy character, is difficult to filter and forms a hard crust when dried. This hard crust has then to be re-ground to the original particle size.
The difficulties caused by the swelling and gummy nature of the sterilized cartilage can be overcome by centrifuging the slurry to form a firm cartilage sediment, decanting the supernatant liquid and replacing it with anhydrous alcohol.
The cartilage sediment, mixed with the anhydrous alcohol, is dehydrated regaining substantially its original particle size and losing its gumminess. This dehydrated cartilage can be readily filtered and dries to a free flowing powder.
Example 13.Sterilization with isopropyl alcohol Anhydrous isopropyl alcohol sterilizes the cartilage as well as 70% ethyl alcohol and in about the same time, i.e., about 30 minutes, without swelling the cartilage particles or causing gumminess.
The cartilage slurry prepared with isopropyl alcohol can be readily filtered and the filter cake so obtained can be dried to a free flowing powder.
The sterilization either with ethyl alcohol or with isopropyl alcohol can be carried out satisfactorily at ambient room temperatures, although sterilization at elevated temperatures may reduce the time required.
Example 14.-Sterilization of the cartilage powder by heat Cartilage powder of the invention, surprisingly, is
sterilized, without loss of wound healing activity, by heating it to about 125-132 C. for 3-4 hours, substantially in the absence of air or oxygen. Other temperatures, as low as 110 C., may be utilized, but for longer periods of time to achieve sterilization.
The preferred procedure is to place the cartilage powder in a vessel with some Dry Ice over it and then covering the vessel loosely with a metal foil. The vessel is placed in a vacuum oven, then oven is connected with a vacuum pump and the air is evacuated to a vacuum of about 10 mm. of mercury. The oven is then heated to about 127 C. and held there for about four hours.
It is important that the entire mass of material in the vessel be heated through and maintained at about 125 to 132 C. for about three to four hours.
The heat sterilized powder is ready for clinical use.
Example 15.Reactivation and enhancement of cartilage by heat in the absence of oxygen This example illustrates lowering of the activity of calf cartilage powder when milled in the presence of air, and air together with heat, respectively, followed by the restoration and further enhancement of the wound-healing activity when the partially or totally inactivated material is exposed to heat of about 127 C. for between 5 hours to 50 hours and in the virtual absence of air or oxygen (Tests 6 and 8).
The cartilage powder was inactivated by hammer milling it under conditions of excessive aeration and some generation of heat (Test 5 The activity of the cartilage was lowered to about one-third of its activity by ball milling it in the presence of air (Test 7), as compared with the same material ball milled in a C atmosphere (Test 4).
The heating of the cartilage was done in the following manner: A vacuum oven (Freas, Size No. 504, Fisher Scientific Co.) was loaded with the cartilage powder and with a small quantity of Dry Ice (solid CO About 15 to 25 grams of the Dry Ice were placed in an open dish in the oven. The door of the oven was closed, the air evacuated to about 10 mm. pressure, the vacuum pump was disconnected, and the heating cycle started. During heating there was some pressure build-up in the oven caused by the expansion of the Dry Ice as it becomes gaseous carbon dioxide.
Rate of wound (7) Calf cartilage, Lot 2AX, ball milled in air (8) #7, heated in CO for /2 hrs., 127
The above test results were based on 20 to over 40 pairs of animals (Sherman strain albino rats) for each of the eight tests enumerated above and the percent figure represents the statistical average of all such tests.
Comparison of Test 3 with Test 2 shows that heat sterilization of the powder of this invention may be accomplished together with enhancement (130.5 vs. 127.7%) of wound healing rate.
Comparison of Test 5 with Test 4 shows that highly effective powder of this invention may be completely deactivated by hammer-milling air with heat generation.
Comparison of Test 6 with Test 5 shows that the thus deactivated hammer-milled powder may be reactivated by prolonged heating as stated.
Comparison of Test 7 with Test 4 shows that ballmilling highly effective powder of the invention in air seriously lowers (from 137.2% to 110.9%) the rate of wound healing.
Comparison of Test 8 with Test 7 shows that heating of the degraded powder of Test 7 in CO at elevated temperature reactivates the material to a highly effective rate of wound healing.
Example 16 Forty wounds involving a wide spectrum of human chronic non-healing types of ulcers were treated according to the present invention.
The types of wounds treated were as follows:
No. of wounds (1) Chronic varicose ulcer on bedrest or after surgical correction of venous incompetency 16 (2) Chronic non-healing ulcers of the abdomen following wound disruption in cachectic patients with inoperable carcinoma 6 (3) Radiation ulcer l (4) Ulcers of the extremities in chronic ulcerative 'colitis (gangreneous pyoderma) 2 There was no particular sex or age distribution except that all were adults and none was older than 60 or younger than 25 years of age.
In each instance the local therapy was:
At the time of the dressing, the wound was thoroughly cleansed with hydrogen peroxide, and washed with alcohol. It was dried with gauze. The cartilage preparation was applied by atomizing the powder onto the surface and into the wound. In 38 of the 40 cases this treatment resulted in the transformation of the wound surface from a non-granulating, sluggish, dirty grey surface to a typical pink, healthy granulating bed within ten days. In the other two cases a somewhat longer time was required.
Example 17 The cartilage powder of the invention was atomized into 83 surgical wounds in 39 human patients with 47 operations, as follows:
CARTILAGE POWDER INSTILLA'IION IN CLOSED SURGICAL WOUNDS o. No. Type of operation Operations Wounds (1) Bilateral phlebectomies 7 43 (2) Cholecystectomy (with and without common duct drainage); right subeostal incision l5 5 (3) Gastrectomy linea alba incision 1 1 (4) Exploratory laparotomy for regional enteritis with emaciation and partial mechanical obstruction, midline incisionl 1 (5) Hysterectomy; midline incision 1 1 (6) Breast biopsy (circum-areolar). l 1 (7) Inguinal herniorrhaphy 22 22 (8) Cecotomy for excision villous adenoma (right lower abdominal oblique) l 1 (9) Lipomectomy 1 1 (10) Pilonidal cystectomy 1 1 (11) Small bowel resection for obstructing mesenterlc tumor metastic from pancreas (midline incision) 1 1 (12) Abdominoperineal resection for squamous cell carcinoma of anus (midline incision) 1 1 (13) Ventral herniorraphy 1 1 (14) Anterior resection of rectosigmoid (midline incision) r 1 1 (15) Resection terminal 30 in. of ileum proximal to ileostomy for regional ileitis; (reopening midline incision used for previous tote colectomy) 1 1 (16) Lysis of adhesions and vagectomy (midline) 1 1 Total Operations 47 Total Wounds 83 In all 83 cases there was primary healing of all wounds except for intermediate suture abscess formation which wsa followed by healing without event. In none of these cases was there any abnormal liver chemistry, disturbed renal function, or evidence of sensitivity to the material of the invention. In no case was the wound non-flexible, thick or keloidal and all wounds appeared to be more flexible and less bulky than normally expected.
Example 18 Calf tracheal cartilage powder having maximum particle size of 40 microns was mixed with about an equal part of anhydrous propylene glycol. This premix was 13 then added to Neobase (an ointment base made by Burroughs -Wellcome & Co. of Tuckahoe, N.Y.) which contains the following ingredients:
diluted with about 50% additional water in an amount to yield a composition having about 10% of said powder.
Thus, a useful wound healing or dermatological salve was formed, although it is to be understood that other ointments and salves and salve bases may incorporate the powder or extract of the present invention.
Example 19 An ointment particularly useful with surgical gauze was formulated by mixing the following:
Parts by Weight Ex. 19-A Ex. 19-B Polyethylene glycol, mol. wt. 4,000 5 Polyethylene glycol, mol. wt. 1,540 30 25 Polyethylene glycol, mol. wt. 300 60 60 Cartilage powder, maximum particle size 40p. 50
This ointment is useful in certain dermatological applications and the physical properties may be further adjusted and controlled by varying the ratios of the polyethylene glycols or adding required amounts of propylene glycol and/or glycerol.
While isotonic saline is an effective extraction medium, more complete extraction with higher healing activity is obtained when the pH is raised slightly with ammonia. Salts other than NaCl provide more elfective extraction, as shown in Example 2. An inert atmosphere during the extraction results in extracts of greater potency than when the extraction is carried out in the presence of oxygen. Since the presence of oxygen during processing has completely inactivated extracts of the cartilages herein shown otherwise to be vastly superior, the use of suitable known non-toxic anti-oxidants such as ascorbic acid or its salts or vitamin A may permit carrying out the extraction in the presence of some air without serious loss of potency.
Though bovine tracheal cartilage from mature animals, i.e., a year old or older, is for some purposes a satisfactory source, cartilage with substantially greater potency is obtained from the skeletons of very young animals. The highest potency material is generally obtained from animals less than one month old, although cartilage from adolescent animals taken before maturity may be used in this invention without excessively fine grinding. Young animals are intended to mean those which are still adolescent and have not yet reached maturity. Cartilage from foetal skeletons is often effective. Finely divided cartilage from other mammals, in addition to bovine and porcine and canine, is effective in healing wounds in accordance with the present invention: for example, finely divided cartilage powder from rat trachea and the human knee have been successfully utilized in accordance with the invention; so also with other animals such as the finely divided cartilage of birds, fish, jaw-bone of shark, rib cage of a crocodile (South American caiman known to be one year old, as obtained from the New York City Zoological Gardens, in early adolescence). Finely divided reptile cartilage is particularly elfective in view of the extraordinary ability of the reptiles to regenerate their tissues and even their limbs.
For example, young cartilage from the tail of a tegu salamander, which tail had regenerated for three months, obtained from the same zoo was used without excessively fine grinding in effective wound-healing experiments. Cartilage from the rib cage of young lambs taken prior to ossification was successfully utilized.
When dry cartilage extract is desired, freeze-drying is preferred, but spray-drying is satisfactory in inert atmosphere. Vacuum drying is satisfactory when oxygen is excluded and temperature of the liquid is held below 40 C.
The cartilage powder may be dusted on the wound or atomized on it. It may also be applied in the form of ointment on the wound, as exemplified above. The extract may also be applied directly to the wound by spraying it on the wound, swabbing it on, or brushing it on. Both the powder and the extract may be applied first to an absorbent medium which is then applied to the wound and held on by a bandage or adhesive tape, or other suitable means. The cartilage or the extract may be incorporated into tablets, capsules or suppositories and applied orally, rectally or in the vaginal or uteral passages. Implantation as pellets and injection of solution of the extract of the invention has been effective.
Cartilage extracts may be injected subcutaneously, intramuscularly or intravenously. The dried extracts may be used as powders or they may be reconstituted and used as the original extracts. The wounds to which the active materials are applied may be sutured or may be left open without materially affecting the rate of healing. The active materials may be administered once, preferably within the first 24 hours of the incision; or they may be applied before the incision or they may be applied in several applications in succession. Irradiating the cartilage powder with ultraviolet radiation in the absence of oxygen increases its activity.
While certain present preferred embodiments of the invention have been described and exemplified herein, it is to be understood that the invention may be otherwise embodied within the spirit thereof and within the scope of the appended claims.
What is claimed is:
1. In the method of sterilizing and enhancing activity of a finely divided cartilage powder having an average particle between about 1 micron and about 40 microns, and a substantial maximum particle size of about 70 microns, which has been aqueous-extracted from granulated defatted acid-pepsin digested essentially pure cartilage freed from adhering tissue, ground, and dried, in the virtual absence of oxygen, in closed-system extraction, grinding and drying means, the improvement which consists of the step of heat-sterilizing such dried ground extracted cartilage powder by heating thoroughly in the virtual absence of oxygen the entire mass of material in a closed-system heating means to about to about- 132 C., for three to four hours.
2. In the method of sterilizing and enhancing activity of a finely divided cartilage powder having an average particle size between about 1 micron and about 40 microns, and a substantial maximum particle size of about 70 microns, which has been aqueous-extracted from granulated defatted acid-pepsin digested essentially pure cartilage freed from adhering tissue, ground, and dried, in the virtual absence of oxygen, in close-system extraction, grinding and drying means, the improvement which consists of the step of sterilizing such dried ground extracted cartilage powder as a slurry with anhydrous isopropyl alcohol without substantially swelling the cartilage powders or causing gumminess.
3. In the method of sterilizing and enhancing activity of a finely divided cartilage powder having an average particle size between about 1 micron and about 40 microns, and a substantial maximum particle size of about 70 microns, which has been aqueous-extracted from granulated defatted acid-pepsin digested essentially pure 15 cartilage freed from adhering tissue, ground, and dried, in the virtual absence of oxygen, in closed-system extraction, grinding and drying means, the improvement which consists of the steps of (1) mixing, at a rate to keep the powder suspended in the liquid, such dried ground extracted cartilage powder, with a sufiicient excess of ethyl alcohol to form a mobile slurry, in which the cartilage swells and becomes somewhat gummy and is difficult to filter and forms a hard crust when dried, which has then to be ground to the original particle size; (2) centrifuging the slurry to form a firm cartilage sediment; (3) decanting the supernatant liquid and replacing References Cited UNITED STATES PATENTS 5/1967 Dingwall et al. 424-95 9/1968 Balassa 424-95 S. K. ROSE, Primary Examiner US. Cl. X.R. 2l2, 58, 93
*zggg UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION 3,476,855 November 4, 1969 Patent No. Dated Inventor-(s) LESLIE L. BALASSA It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 2, line 67, after "harm" for "is" read -if--. Col. 3, line 19, for "provide" read --provides--; line 20, for "helaing" read -healing. Column 8, line 21, for "Approximatel read -Approximate-. Column 10, line 72, for "then" read -the- Column 12, line 65, change "wsa" to -was-. Column 14, line 44 (claim 1) after "particle" insert --size--; line 64 (claim 2) f0. "close-system" read -closedsystem-.
SIGNED AND SEALED JUN161970 Amt:
Emirmm 1:. .m Atteatmg Offioor Oomissioner of Patents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US435693A US3400199A (en) | 1965-02-26 | 1965-02-26 | Wound-healing cartilage powder |
US69842668A | 1968-01-17 | 1968-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3476855A true US3476855A (en) | 1969-11-04 |
Family
ID=27030649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US698426A Expired - Lifetime US3476855A (en) | 1965-02-26 | 1968-01-17 | Sterilizing and enhancing activity of a finely divided cartilage powder |
Country Status (1)
Country | Link |
---|---|
US (1) | US3476855A (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966908A (en) * | 1973-11-29 | 1976-06-29 | Lescarden Ltd. | Method of treating degenerative joint afflictions |
US4191747A (en) * | 1976-12-17 | 1980-03-04 | Hans Scheicher | Corrective agent for the covering and/or filling of bone defects, method for the preparation of same and method of using the same |
WO1980002501A1 (en) * | 1979-05-11 | 1980-11-27 | Lescarden Ltd | Cartilage extraction processes and products |
US4469676A (en) * | 1983-06-21 | 1984-09-04 | Michel Hecmati | Method for eliminating wrinkles occurring in the human skin |
US4486416A (en) * | 1981-03-02 | 1984-12-04 | Soll David B | Protection of human and animal cells subject to exposure to trauma |
WO1993010712A1 (en) * | 1991-12-06 | 1993-06-10 | The General Hospital Corporation | Cartilage degradation assay system |
US5360593A (en) * | 1987-12-29 | 1994-11-01 | Alcon Laboratories, Inc. | Heat sterilization of labile antibiotics |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US20050288796A1 (en) * | 2004-06-23 | 2005-12-29 | Hani Awad | Native soft tissue matrix for therapeutic applications |
US20100241228A1 (en) * | 2006-07-07 | 2010-09-23 | Carina Syring | Engineered osteochondral construct for treatment of articular cartilage defects |
US20100274362A1 (en) * | 2009-01-15 | 2010-10-28 | Avner Yayon | Cartilage particle tissue mixtures optionally combined with a cancellous construct |
US20100322994A1 (en) * | 2003-12-11 | 2010-12-23 | Isto Technologies, Inc. | Particulate cartilage system |
US20110196508A1 (en) * | 2003-04-29 | 2011-08-11 | Katherine Gomes Truncale | Cartilage repair mixture containing allograft chondrocytes |
US20110224797A1 (en) * | 2007-01-24 | 2011-09-15 | Semler Eric J | Two piece cancellous construct for cartilage repair |
US8221500B2 (en) | 2003-05-16 | 2012-07-17 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US8292968B2 (en) | 2004-10-12 | 2012-10-23 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
US8480757B2 (en) | 2005-08-26 | 2013-07-09 | Zimmer, Inc. | Implants and methods for repair, replacement and treatment of disease |
US8497121B2 (en) | 2006-12-20 | 2013-07-30 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
US8642061B2 (en) * | 2007-06-15 | 2014-02-04 | Warsaw Orthopedic, Inc. | Method of treating bone tissue |
US9138318B2 (en) | 2007-04-12 | 2015-09-22 | Zimmer, Inc. | Apparatus for forming an implant |
US9675645B2 (en) * | 2013-01-22 | 2017-06-13 | Warsaw Orthopedic, Inc. | Method of preparing bone material having enhanced osteoinductivity |
US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US10167447B2 (en) | 2012-12-21 | 2019-01-01 | Zimmer, Inc. | Supports and methods for promoting integration of cartilage tissue explants |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3318774A (en) * | 1961-03-15 | 1967-05-09 | Squibb & Sons Inc | Treatment of osseous and other tissue |
US3400199A (en) * | 1965-02-26 | 1968-09-03 | Leslie L. Balassa | Wound-healing cartilage powder |
-
1968
- 1968-01-17 US US698426A patent/US3476855A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3318774A (en) * | 1961-03-15 | 1967-05-09 | Squibb & Sons Inc | Treatment of osseous and other tissue |
US3400199A (en) * | 1965-02-26 | 1968-09-03 | Leslie L. Balassa | Wound-healing cartilage powder |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966908A (en) * | 1973-11-29 | 1976-06-29 | Lescarden Ltd. | Method of treating degenerative joint afflictions |
US4191747A (en) * | 1976-12-17 | 1980-03-04 | Hans Scheicher | Corrective agent for the covering and/or filling of bone defects, method for the preparation of same and method of using the same |
WO1980002501A1 (en) * | 1979-05-11 | 1980-11-27 | Lescarden Ltd | Cartilage extraction processes and products |
US4350682A (en) * | 1979-05-11 | 1982-09-21 | Lescarden Ltd. | Cartilage extraction processes and products |
US4486416A (en) * | 1981-03-02 | 1984-12-04 | Soll David B | Protection of human and animal cells subject to exposure to trauma |
US4469676A (en) * | 1983-06-21 | 1984-09-04 | Michel Hecmati | Method for eliminating wrinkles occurring in the human skin |
US5360593A (en) * | 1987-12-29 | 1994-11-01 | Alcon Laboratories, Inc. | Heat sterilization of labile antibiotics |
WO1993010712A1 (en) * | 1991-12-06 | 1993-06-10 | The General Hospital Corporation | Cartilage degradation assay system |
US5284155A (en) * | 1991-12-06 | 1994-02-08 | The General Hospital Corporation | Cartilage degradation assay system |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US20110196508A1 (en) * | 2003-04-29 | 2011-08-11 | Katherine Gomes Truncale | Cartilage repair mixture containing allograft chondrocytes |
USRE43258E1 (en) | 2003-04-29 | 2012-03-20 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US8221500B2 (en) | 2003-05-16 | 2012-07-17 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US8765165B2 (en) | 2003-12-11 | 2014-07-01 | Zimmer, Inc. | Particulate cartilage system |
US8518433B2 (en) | 2003-12-11 | 2013-08-27 | Zimmer, Inc. | Method of treating an osteochondral defect |
US8834914B2 (en) | 2003-12-11 | 2014-09-16 | Zimmer, Inc. | Treatment methods using a particulate cadaveric allogenic juvenile cartilage particles |
US8652507B2 (en) | 2003-12-11 | 2014-02-18 | Zimmer, Inc. | Juvenile cartilage composition |
US20100322994A1 (en) * | 2003-12-11 | 2010-12-23 | Isto Technologies, Inc. | Particulate cartilage system |
US8784863B2 (en) | 2003-12-11 | 2014-07-22 | Zimmer, Inc. | Particulate cadaveric allogenic cartilage system |
US8524268B2 (en) | 2003-12-11 | 2013-09-03 | Zimmer, Inc. | Cadaveric allogenic human juvenile cartilage implant |
US20050288796A1 (en) * | 2004-06-23 | 2005-12-29 | Hani Awad | Native soft tissue matrix for therapeutic applications |
US8292968B2 (en) | 2004-10-12 | 2012-10-23 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
US8480757B2 (en) | 2005-08-26 | 2013-07-09 | Zimmer, Inc. | Implants and methods for repair, replacement and treatment of disease |
US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US20100241228A1 (en) * | 2006-07-07 | 2010-09-23 | Carina Syring | Engineered osteochondral construct for treatment of articular cartilage defects |
US8497121B2 (en) | 2006-12-20 | 2013-07-30 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
US8906110B2 (en) | 2007-01-24 | 2014-12-09 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US20110224797A1 (en) * | 2007-01-24 | 2011-09-15 | Semler Eric J | Two piece cancellous construct for cartilage repair |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
US9138318B2 (en) | 2007-04-12 | 2015-09-22 | Zimmer, Inc. | Apparatus for forming an implant |
AU2008265852B2 (en) * | 2007-06-15 | 2014-04-17 | Warsaw Orthopedic, Inc. | Method of treating tissue |
US8642061B2 (en) * | 2007-06-15 | 2014-02-04 | Warsaw Orthopedic, Inc. | Method of treating bone tissue |
US20100274362A1 (en) * | 2009-01-15 | 2010-10-28 | Avner Yayon | Cartilage particle tissue mixtures optionally combined with a cancellous construct |
US10167447B2 (en) | 2012-12-21 | 2019-01-01 | Zimmer, Inc. | Supports and methods for promoting integration of cartilage tissue explants |
US9675645B2 (en) * | 2013-01-22 | 2017-06-13 | Warsaw Orthopedic, Inc. | Method of preparing bone material having enhanced osteoinductivity |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US11555172B2 (en) | 2014-12-02 | 2023-01-17 | Ocugen, Inc. | Cell and tissue culture container |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3400199A (en) | Wound-healing cartilage powder | |
US3476855A (en) | Sterilizing and enhancing activity of a finely divided cartilage powder | |
US3478146A (en) | Wound-healing cartilage powder extracting process | |
USRE28093E (en) | Wound-healing cartilage powder | |
CN103520764B (en) | Functional dressing, and preparation method and application thereof | |
AU778792B2 (en) | Composition and method for enhancing wound healing | |
EP3308793B1 (en) | Therapeutic agent for skin wound or rough skin | |
Greenwood et al. | Hyperbaric oxygen and wound healing in post-irradiation head and neck surgery | |
JPH0674208B2 (en) | Use of GHL-Cu as wound healing and anti-inflammatory agent | |
PT671922E (en) | FLUIDIZED INTESTINAL SUBMUCOSA AND ITS USE AS AN INJECTABLE FABRIC FIBER | |
JPH07500095A (en) | Hemostatic composition for local hemostasis | |
CN111773429A (en) | Hydrogel dressing and preparation method thereof and multifunctional nanocomposite dressing and preparation method and application thereof | |
Sekiya et al. | Treatment of infectious skin defects or ulcers with electrolyzed strong acid aqueous solution | |
EP0146742A1 (en) | Use of ubidecarenone for the preparation of a medicament for treating ulcers caused by radiotherapy | |
JP7378486B2 (en) | Medical adhesives, their preparation methods, and their uses | |
REISER et al. | Tryptic debridement of necrotic tissue | |
WO2003041723A1 (en) | Pharmaceutical applications of hyaluronic acid preparations | |
CN105879006A (en) | Pharmaceutical composition for treating diabetic foot ulcer as well as preparation method and application of pharmaceutical composition | |
CN118593756A (en) | A biological dressing containing recombinant collagen and its preparation method and application | |
KR101820519B1 (en) | Use of sulglycotide for promoting skin-wound-healing, and composition for external application comprising the same | |
CN104490760A (en) | Preparation method and application of capsaicin-collagen sponge | |
EP0137743A2 (en) | Topically administrable pharmaceutical compositions | |
US2717227A (en) | Composition containing nerve tissue extract and process of producing such extract | |
JPH04500799A (en) | Copolymer of vinyl acetate and vinyl alcohol crosslinked with glutaraldehyde, method for producing the same, and pharmaceuticals based on the same | |
RU2108078C1 (en) | Method for treating deep burn wounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CATRIX RESEARCH LIMIED PARTNERSHIP, 306 SOUTH STAT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:LESCARDEN LTD.;REEL/FRAME:004037/0086 Effective date: 19820601 |